AMGEN INC — Director's Dealing 2025

Feb 22, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AMGEN INC (AMGN)
CIK: 0000318154
Period of Report: 2025-02-19

Reporting Person: Santos Esteban (EVP, Operations)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-02-19	Common Stock	M	8711	$156.35	Acquired	80257	Direct
2025-02-19	Common Stock	S	8711	$292.837	Disposed	71546	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-02-19	Nqso (Right to Buy)	$156.35	M	8711	Disposed	2026-05-03	Common Stock (8711)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	868.8725	Indirect

Footnotes

F1: These shares were acquired in connection with the exercise of stock options expiring on May 3, 2026.

F2: The price reported is an average price. The prices ranged from $292.7523 to $293.00 per share. Full information regarding the number of shares purchased at each separate price within the range is available upon request by the SEC staff, the issuer or a security holder of the issuer.

F3: These shares include 667 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

F4: These shares are acquired under the Company's 401(k) Plan and represent interests in the Company's stock fund as of this filing.